Brief Description
The purpose of this study is to evaluate the safety and efficacy of BION-1301 in adults with IgA nephropathy.
Estimated Enrollment
350
Estimated End Date
June 2028
Trial is for people with
Primary immunoglobulin A nephropathy (IgAN) at risk of progressive loss of kidney function.
Study Goal
The goal of the BEYOND study is to evaluate the safety and efficacy of zigakibart in reducing proteinuria and slowing down kidney ...
What is involved for the patient?
Patients will have assessments of safety and efficacy every 2 weeks over 2 years. Patients will also be followed up for safety for an ...
About the drug or intervention
Zigakibart (BION-1301) is a novel, humanized monoclonal antibody that binds and blocks APRIL (A PRoliferation-Inducing Ligand).